At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NEXI NexImmune, Inc.
Pre-Market Trading 05-14 06:51:06 EDT
3.41
-0.19
-5.28%
High3.56
Low3.39
Vol9.06K
Open3.50
D1 Closing3.60
Amplitude4.83%
Mkt Cap4.68M
Tradable Cap3.51M
Total Shares1.37M
T/O31.47K
T/O Rate0.88%
Tradable Shares1.03M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Analysts Offer Insights on Technology Companies: Solutions 30 SE (30L3) and Nexi S.p.A. (Milan: IT:NEXI)
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. The company was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.